Valeritas said today that data from a study of its V-Go insulin pump showed a significant decrease in A1C levels after 14 and 27-week follow-up visits.
Data from the study was published in the journal Diabetes Therapy this week, the company said.
“Tight glycemic control and timely treatment can improve outcomes in patients with diabetes, yet many remain sub-optimally controlled. Basal insulin therapy is sufficient for many patients; however despite optimization of basal insulin evidence suggests less than 40% of patients with type 2 diabetes achieve glycemic targets. Previous studies have reported that patients using the V-Go disposable insulin delivery device experience improved glycemic control with favorable patient acceptance. We aimed to explore these earlier findings by evaluating patient outcomes in our diabetes centers, located across Texas,” lead author Dr. Rosemarie Lajara said in prepared remarks.
V-Go is a disposable, wearable insulin delivery device designed to deliver a preset dosage continually over 24 hours and on-demand doses during meals.
The 204-patient trial reported a 1.53% baseline reduction in HbA1c levels at 14 weeks and 1.79% after 27 weeks in patients treated with the device. The rate of hypoglycemic events was similar between control and V-Go groups, the company said.
“The study results show that V-Go is safe and effective in patients with sub-optimally controlled diabetes requiring insulin therapy. Glycemic control improved signiﬁcantly, less insulin was required, and hypoglycemic events were similar after patients switched to insulin delivery by V-Go,” Dr. Lajara said in a press release.
In May, Valeritas touted real-world data from 3 separate studies of its V-Go insulin delivery system showcasing the device’s utility and effectiveness.
The 1st study looked at 153 patients and how they fared switching to the V-Go system from either multiple daily insulin injections, long-acting basal insulin therapy or no treatment. Each cohort showed improvement in glycemic control on V-Go through several follow-ups, and the group that was previously on insulin injections needed less with the company’s device.